Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade A 104.08 1.86% 1.90
ABBV closed up 1.33 percent on Monday, November 23, 2020, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ABBV trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 1.86%
New 52 Week High Strength 1.86%
Overbought Stochastic Strength 1.86%
Up 3 Days in a Row Strength 1.86%
New 52 Week Closing High Bullish 3.21%
Pocket Pivot Bullish Swing Setup 3.21%
New 52 Week High Strength 3.21%
Multiple of Ten Bullish Other 3.21%
Overbought Stochastic Strength 3.21%
1,2,3 Pullback Bullish Bullish Swing Setup 4.42%
Older End-of-Day Signals for ABBV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace 13 minutes ago
Rose Above Previous Day's High 29 minutes ago
New 52 Week High 29 minutes ago
Up 1% 29 minutes ago
60 Minute Opening Range Breakdown about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Chemistry Chemical Compounds Organic Compounds Autoimmune Diseases Pharmaceutical Products Prostate Cancer Chloroarenes Cardiology Cholesterol Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Secondary Hyperparathyroidism Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Lipoproteins Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 102.76
52 Week Low 62.55
Average Volume 8,332,600
200-Day Moving Average 89.60
50-Day Moving Average 89.60
20-Day Moving Average 93.70
10-Day Moving Average 99.26
Average True Range 2.45
ADX 38.7
+DI 40.73
-DI 12.29
Chandelier Exit (Long, 3 ATRs ) 95.42
Chandelier Exit (Short, 3 ATRs ) 86.45
Upper Bollinger Band 107.35
Lower Bollinger Band 80.05
Percent B (%b) 0.81
BandWidth 29.13
MACD Line 3.67
MACD Signal Line 2.97
MACD Histogram 0.702
Fundamentals Value
Market Cap 180.33 Billion
Num Shares 1.76 Billion
EPS 4.57
Price-to-Earnings (P/E) Ratio 22.35
Price-to-Sales 3.92
Price-to-Book 11.52
PEG Ratio 1.28
Dividend 5.20
Dividend Yield 5.09%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 104.72
Resistance 3 (R3) 104.63 103.69 104.29
Resistance 2 (R2) 103.69 103.05 103.74 104.15
Resistance 1 (R1) 102.94 102.65 103.32 103.03 104.01
Pivot Point 102.00 102.00 102.19 102.05 102.00
Support 1 (S1) 101.25 101.36 101.63 101.34 100.35
Support 2 (S2) 100.31 100.96 100.36 100.21
Support 3 (S3) 99.56 100.31 100.07
Support 4 (S4) 99.65